Linked Life Data

17825674

Source:http://linkedlifedata.com/resource/pubmed/id/17825674

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-9-10
pubmed:abstractText
Adverse pregnancy outcome (APO), includes fetal loss > or =20 weeks' gestation (fetal death), severe preeclampsia <36 weeks, or severe intrauterine growth restriction (severe IUGR) defined as birth weight < or =5th percentile or < or =10th percentile for gestational age. APO affects 8% of pregnant women (320,000 annually) and collectively contributes to the largest proportion of maternal/fetal mortality and morbidity. Women with prior APO in antecedent pregnancy are at high risk of an adverse maternal or fetal outcome in the subsequent pregnancy. Maternal serum markers and Doppler ultrasound can be used to predict adverse pregnancy outcome. There are no adequate, completed randomized trials for prophylactic measures; the roles of aspirin, calcium, and low molecular weight heparin need to be evaluated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0146-0005
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
208-12
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.
pubmed:affiliation
Yale Women & Children's Center for Blood Disorders, Yale University School of Medicine, New Haven, CT 06520, USA. michael.paidas@yale.edu
pubmed:publicationType
Journal Article, Review